Most prominently, a large phase 3 trial of an IDO1 enzyme inhibitor plus a PD-1 inhibitor in metastatic melanoma did not result in greater clinical benefit compared to PD-1 inhibition alone [77]. Here, IDO1 is linked to metastatic melanoma.